Erleada

(apalutamide) Janssen

Composition:

• Available in film-coated tablet with each contains 60 mg of apalutamide for oral administration

Indication:

• For the treatment of patients with metastatic castration-sensitive prostate cancer or non-metastatic castration-resistant prostate cancer

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.
The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.